Japanese encephalitis virus and its mechanisms of neuroinvasion

Justin T. Hsieh, Ashley L. St. John

1 Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore, 2 Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 3 SingHealth Duke-NUS Global Health Institute, Singapore, 4 Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America

* ashley.st.john@duke-nus.edu.sg

Introduction

Japanese encephalitis virus (JEV) is a positive-sense single-stranded RNA virus of the Flavivirus genus that is spread by Culex mosquitos. It is maintained in an enzootic cycle in pigs and wild birds in which humans are dead-end hosts [1]. Despite having effective vaccines, JEV is the leading cause of viral encephalitis in Asia [1]. As a neuroinvasive virus, it can effectively cross the blood–brain barrier (BBB) to cause acute encephalitis. Twenty-five percent to 30% of Japanese encephalitis (JE) cases are fatal, and 50% result in permanent neuropsychiatric complications [2]. There are currently no treatments for JE, partly due to an incomplete understanding of the mechanisms promoting encephalitis.

The central nervous system (CNS) relies on the BBB, a tightly regulated barrier between the peripheral circulation and the CNS, to prevent entry of pathogens, including viruses. Yet, JEV and other neuroinvasive viruses can overcome the BBB, which usually excludes foreign substances. It is formed primarily by tight junctions (TJ) between endothelial cells, comprised of proteins such as claudin-5, zonula occludens (ZO)-1, and occludin. The BBB is sustained by supporting cell types, including astrocytes, pericytes, microglia, and mast cells (MCs) [1, 3]. Together, these cells form neurovascular units that maintain a barrier along the cerebrovascular microvessels to promote immune privilege and CNS homeostasis [3, 4].

Neuroinvasive viruses use several mechanisms to access the CNS: (1) direct infection of endothelial cells and subsequent transcellular release of virus into the brain parenchyma, (2) infection of peripheral immune cells that enter the CNS in a “Trojan Horse” mechanism, (3) paracellular entry following breakdown of the BBB, (4) retrograde transport of virus from the peripheral nervous system (PNS) into the CNS, and (5) translocation from the blood to the cerebral spinal fluid (CSF) [5, 6] (Fig 1). JEV infection through the natural subcutaneous route leads to widespread infection in various parts of the brain [7], suggesting a hematological route of infection, such as would occur for mechanisms 1–3. Here we provide an overview of a few described mechanisms of JEV penetration of the BBB and processes that amplify CNS infection.

Transcellular infection of endothelial cells and activation of the neurovascular unit

Some neurotropic viruses directly infect endothelial cells to reach the brain from the circulation and travel transcellularly to release viruses into the brain parenchyma [6]. JEV has been
visualized intracellularly in vesicles using electron microscopy and was suggested to undergo transcytosis across endothelial cells through pericytes into the brain of infected suckling mice [3]. JEV antigens have not been observed in brain endothelial cells in virus-infected adult mice [8] or consistently observed in brain specimens from fatal JE patients [9], but this mechanism of neuroinvasion could potentially contribute to CNS infection. Cell-culture studies have also shown that endothelial cells may transiently propagate JEV to other supporting cells such as astrocytes, which can subsequently be activated [10].
Paracellular infection is promoted by MCs

Neurotropic viruses can gain entry into the brain through compromising the BBB. This occurs when TJs between endothelial cells become leaky, often due to the proinflammatory response. That JEV gains entry into the brain through cleaved TJs is supported by reduced resistance across JEV-exposed cultured brain-endothelial-cell membranes in vitro [11] and increased BBB leakiness and TJ protein breakdown in mouse models [12]. MCs are an important population of CNS-resident immune cells recently implicated in BBB compromise during JEV infection [12]. Indeed, MC depletion from the CNS reduced BBB breakdown and JEV penetration of the brain in mice [12]. In addition to their presence within the brain, MCs are also one of the first immune cell types JEV encounters in the periphery. JEV causes MC degranulation, which enhances JEV-induced breakdown of the BBB and augments infection in the brain [13]. In particular, MC-derived chymase, a vasoactive protease, played a functionally significant role in breakdown of TJ proteins, including ZO-1, ZO-2, claudin-5, and occludin, ultimately leading to increased BBB compromise (Fig 2). This was restored with either pharmacological inhibition of chymase or genetic knockout of the mouse-chymase MCPT4 [2]. In vivo, therapeutically inhibiting chymase reduced JEV penetration of the BBB and reduced the morbidity and mortality associated with JE [12]. Thus, MCs facilitate paracellular entry of JEV across the BBB.

Other peripheral myeloid cells may contribute to neuroinvasion

Another potential pathway establishing CNS infection is through infection of peripheral immune cells that can subsequently gain entry into the CNS in a “Trojan Horse” mechanism. For JEV infection, macrophages [11] and DCs [14] are suspected peripheral infection cell targets. Furthermore, macrophages are the predominant infiltrated immune cells in fatal JEV brain samples [13]. However, in vivo experiments, thus far, have failed to identify infected macrophages in CNS tissues at the time points tested [11]. This does not rule out the possibility of low titer introduction of a virus into the CNS in this manner, but further investigation is needed. Alternatively, peripheral macrophages may indirectly promote neuroinvasion through the release of other mediators, such as reactive oxygen species (ROS) and MMP-9 [13] (Fig 2). In contrast to the suspected role of macrophages in BBB compromise during JE, JEV-infected DCs promote anti-inflammatory regulatory T cells (T-regs) while inhibiting proinflammatory Th-17 T cells and monocyte differentiation [15, 16]. These modulations are thought to result in improved BBB integrity and reduced viral entry into the CNS, demonstrating the dual contributions of peripheral immune responses to BBB integrity and infection control.

Amplification of BBB leakiness by JEV infection within the brain

Once present in the CNS, inflammation due to JEV amplifies BBB breakdown. Pericytes, which are situated within the basement membrane next to endothelial cells, aid in breakdown of the BBB through release of IL-6, which leads to ZO-1 degradation [17]. Coculture of astrocytes and brain endothelial cells increases TJ leakiness through increased release of mediators such as IL-6, CCL5, and CXCL10 [17] (Fig 2). Microglia also release proinflammatory mediators such as TNF-α to promote BBB leakiness [17]. At the latter stages of disease, CNS-supporting cells are activated and accentuate BBB leakiness and disease, but this increased permeability may also allow penetration of immune cells that are necessary for infection clearance, such as T cells [18].
Another factor that has been implicated in accentuating BBB breakdown during JEV infection are interferons (IFNs). Quick induction of type I IFNs has been associated with protection of astrocytes from apoptosis [19] and protection from lethal infection in mice [20]. Similarly, IFNγ was shown to contribute to protection from CNS infection [18]. In contrast, targeting of IFNγ with a neutralizing antibody improved BBB integrity in one study, suggesting its role in enhancing BBB permeability [21].
Concluding remarks

JEV causes high morbidity and mortality in humans, leading to permanent neurological deficits, even in those who survive. Recent reports have advanced our understanding of the pathophysiological events that allow JEV to traverse the BBB and cause encephalitis. Although multiple routes of CNS entry are plausible, paracellular penetration of viruses resulting from protease and cytokine-driven breakdown of the BBB appears to be the dominant mechanism for JEV neuropenetration. This new knowledge may aid to the development of therapeutics for the treatment of virally induced encephalitis.

Acknowledgments

We thank Abhay Rathore for critical manuscript review.

References

1. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011; 89(10):766–74, 74A-74E. https://doi.org/10.2471/BLT.10.085233 PMID: 22084515; PubMed Central PMCID: PMC3209971.
2. Yun S-I, Lee Y-M. Japanese encephalitis. Human Vaccines & Immunotherapeutics. 2014; 10(2):263–79. https://doi.org/10.4161/hv.26902 PMID: 24161909.
3. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiology of Disease. 2010; 37(1):13–25. https://doi.org/10.1016/j.nbd.2009.07.030 PMID: 19664713.
4. Khalil M, Ronda J, Weintraub M, Jain K, Silver R, Silverman AJ. Brain mast cell relationship to neurovasculature during development. Brain Res. 2007; 1171:18–29. https://doi.org/10.1016/j.brainres.2007.07.034 PMID: 17764664; PubMed Central PMCID: PMC2049068.
5. Phillips AT, Rico AB, Strauf CB, Hammond SL, Aboellail TA, Tjalkens RB, et al. Entry Sites of Venezuelan and Western Equine Encephalitis Viruses in the Mouse Central Nervous System following Peripheral Infection. J Virol. 2016; 90(12):5785–96. https://doi.org/10.1128/JVI.03219-15 PMID: 27053560; PubMed Central PMCID: PMC4886771.
6. Cain MD, Salimi H, Diamond MS, Klein RS. Mechanisms of Pathogen Invasion into the Central Nervous System. Neuron. 2019; 103(5):771–83. Epub 2019/09/06. https://doi.org/10.1016/j.neuron.2019.07.015 PMID: 31487528.
7. Johnson RT, Burke DS, Elwell M, Leake CJ, Nisalak A, Hoke CH, et al. Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Ann Neurol. 1985; 18(5):567–73. https://doi.org/10.1002/ana.410180510 PMID: 3000282.
8. Lai CY, Ou YC, Chang CY, Pan HC, Chang CJ, Liao SL, et al. Endothelial Japanese encephalitis virus infection enhances migration and adhesion of leukocytes to brain microvascular endothelia via MEK-dependent expression of ICAM1 and the CINC and RANTES chemokines. Journal of neurochemistry. 2012; 123(2):250–61. https://doi.org/10.1111/j.1471-4159.2012.07889.x PMID: 22845610.
9. Liou ML, Hsu CY. Japanese encephalitis virus is transported across the cerebral blood vessels by endocytosis in mouse brain. Cell Tissue Res. 1998; 293(3):389–94. https://doi.org/10.1007/s004410051130 PMID: 9716728.
10. Patabendige A, Michael BD, Craig AG, Solomon T. Brain microvascular endothelial-astrocyte cell responses following Japanese encephalitis virus infection in an in vitro human blood-brain barrier model. Mol Cell Neurosci. 2018; 89:60–70. Epub 2018/04/11. https://doi.org/10.1016/j.mcn.2018.04.002 PMID: 29635016; PubMed Central PMCID: PMC5984247.
11. German AC, Myint KS, Mai NT, Pomeroy I, Phu NH, Tzartos J, et al. A preliminary neuropathological study of Japanese encephalitis in humans and a mouse model. Trans R Soc Trop Med Hyg. 2006; 100(12):1135–45. https://doi.org/10.1016/j.trstmh.2006.02.008 PMID: 16814333.
12. Hsieh JT, Rathore APS, Soundarajan G, St John AL. Japanese encephalitis virus neuropenetration is driven by mast cell chymase. Nat Commun. 2019; 10(1):706. https://doi.org/10.1038/s41467-019-08641-z PMID: 30742006; PubMed Central PMCID: PMC6370686.
13. Dutta K, Mishra MK, Nazmi A, Kumawat KL, Basu A. Minocycline differentially modulates macrophage mediated peripheral immune response following Japanese encephalitis virus infection. Immunobiology. 2010; 215(11):884–93. https://doi.org/10.1016/j.imbio.2009.12.003 PMID: 20153075.
14. Boothpur R, Brennan DC. Human polyoma viruses and disease with emphasis on clinical BK and JC. J Clin Virol. 2010; 47(4):306–12. https://doi.org/10.1016/j.jcv.2009.12.006 PMID: 20060360; PubMed Central PMCID: PMC3774018.

15. Kim JH, Choi JY, Kim SB, Uyangaa E, Patil AM, Han YW, et al. CD11c(hi) Dendritic Cells Regulate Ly-6C(hi) Monocyte Differentiation to Preserve Immune-privileged CNS in Lethal Neuroinflammation. Sci Rep. 2015; 5:17548. https://doi.org/10.1038/srep17548 PMID: 26626303; PubMed Central PMCID: PMC4667186.

16. Choi JY, Kim JH, Patil AM, Kim SB, Uyangaa E, Hossain FMA, et al. Exacerbation of Japanese Encephalitis by CD11c(hi) Dendritic Cell Ablation Is Associated with an Imbalance in Regulatory Foxp3(+) and IL-17(+)CD4(+) T Cells and in Ly-6C(hi) and Ly-6C(lo) Monocytes. Immune Netw. 2017; 17(3):192–200. https://doi.org/10.4110/in.2017.17.3.192 PMID: 28680381; PubMed Central PMCID: PMC5484650.

17. Lannes N, Summerfield A, Filgueira L. Regulation of inflammation in Japanese encephalitis. J Neuroinflammation. 2017; 14(1):158-. https://doi.org/10.1186/s12974-017-0931-5 PMID: 28807053.

18. Larena M, Regner M, Lobigs M. Cytolytic effector pathways and IFN-gamma help protect against Japanese encephalitis. Eur J Immunol. 2013; 43(7):1789–98. Epub 2013/04/10. https://doi.org/10.1002/eji.201243152 PMID: 23568450.

19. Lindqvist R, Mundt F, Gilthorpe JD, Wolfel S, Gekara NO, Kroger A, et al. Fast type I interferon response protects astrocytes from flavivirus infection and virus-induced cytopathic effects. J Neuroinflammation. 2016; 13(1):277. Epub 2016/10/26. https://doi.org/10.1186/s12974-016-0748-7 PMID: 27776548; PubMed Central PMCID: PMC5079952.

20. Han YW, Choi JY, Uyangaa E, Kim SB, Kim JH, Kim BS, et al. Distinct dictation of Japanese encephalitis virus-induced neuroinflammation and lethality via triggering TLR3 and TLR4 signal pathways. PLoS Pathog. 2014; 10(9):e1004319. Epub 2014/09/05. https://doi.org/10.1371/journal.ppat.1004319 PMID: 25186232; PubMed Central PMCID: PMC4154777.

21. Li F, Wang Y, Yu L, Cao S, Wang K, Yuan J, et al. Viral Infection of the Central Nervous System and Neuroinflammation Precede Blood-Brain Barrier Disruption during Japanese Encephalitis Virus Infection. J Virol. 2015; 89(10):5602–14. Epub 2015/03/13. https://doi.org/10.1128/JVI.00143-15 PMID: 25762733; PubMed Central PMCID: PMC4442524.